Observational studyFrontiers in cellular and infection microbiology2026
Altered expression of ADAR1, N4BP1, and PSME1 in PBMCs correlated with therapeutic outcomes in HBeAg-negative chronic hepatitis B patients treated with Peg-IFN-α.
Observational study in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aims: Pegylated interferon alpha (Peg-IFN-α) has the potential for eradicating hepatitis B surface antigen (HBsAg). The aim of our study is to investigate whether the expression levels of adenosine deaminase acting on RNA 1 (ADAR1), NEDD4-binding protein 1 (N4BP1), proteasome activator complex subunit 1 (PSME1) mRNAs in peripheral blood mononuclear cells (PBMCs) of HBeAg-negative chronic hepatitis B virus (HBV) patients are associated with the response to Peg-IFN-α treatment and HBsAg clearance. Methods: In this prospective study, HBeAg-negative chronic HBV patients treated with Peg-IFN-α were followed for 48 weeks. Patients were categorized into the virological response (VR) group and non-virological response (NVR) group based on the observed changes in HBV DNA and HBsAg levels at week 48 of treatment. Additionally, patients were classified into a serological response (SR) group and a non-serological response (NSR) group according to whether serum HBsAg loss or seroconversion occurred. The expression levels of ADAR1, N4BP1, and PSME1 mRNAs in PBMCs were detected by real-time quantitative PCR. The diagnostic performance of ADAR1, N4BP1, and PSME1 was assessed by analyzing the receiver operating characteristic (ROC) curve and calculating the area under the curve (AUC). Results: After the treatment period, the VR and SR rates were 47.25% and 35.16%, respectively. Dynamic changes in ADAR1, N4BP1, and PSME1 mRNA levels differed significantly between the VR and NVR groups, as well as between the SR and NSR groups. Multivariate analysis revealed that ADAR1 was independently associated with VR and SR at weeks 12 and 24; N4BP1 was independently associated with VR at weeks 12 and 24; PSME1 was independently associated with VR and SR at weeks 12 and 24. At week 24, the AUCs for ADAR1 in predicting VR and SR were 0.9230 and 0.8554. N4BP1 had AUCs of 0.7393 for VR at week 12 and 0.7198 for SR at week 24, while PSME1 had AUCs of 0.7418 for VR and 0.7426 for SR at week 12. Conclusions: ADAR1, N4BP1, and PSME1 are novel biomarkers for early therapeutic response to Peg-IFN-α and HBsAg clearance. Clinical Trial Registration: https://www.medicalresearch.org.cn/login, identifier 2023-311.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.